Classification of ovarian carcinomas based on pathology and molecular genetics

被引:0
作者
Emanuela D’Angelo
Jaime Prat
机构
[1] Autonomous University of Barcelona,Department of Pathology Hospital de la Santa Creu i Sant Pau
来源
Clinical and Translational Oncology | 2010年 / 12卷
关键词
Ovary; Carcinoma; Pathology; Molecular genetics;
D O I
暂无
中图分类号
学科分类号
摘要
Malignant epithelial tumours (carcinomas) are the most common ovarian cancers and the most lethal gynaecological malignancies. Based on light microscopy and molecular genetics, ovarian carcinomas are subdivided into at least five main subtypes that account for over 95% of cases and are inherently different diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and outcome. For successful subtype-specific treatment, reproducible pathological diagnosis of tumour cell type is critical. Recent investigations have also demonstrated that a significant number of cancers traditionally thought to be primary ovarian tumours (particularly serous, endometrioid and clear cell carcinomas) originate in the fallopian tube and the endometrium and involve the ovary secondarily. In this review we summarise recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.
引用
收藏
页码:783 / 787
页数:4
相关论文
共 81 条
  • [1] Gilks C.B.(2009)Ovarian carcinoma pathology and genetics: recent advances Hum Pathol 40 1213-1223
  • [2] Prat J.(2003)Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 484-486
  • [3] Singer G.(2005)Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis Am J Surg Pathol 29 218-224
  • [4] Oldt R.(2006)The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 230-236
  • [5] Cohen Y.(2007)Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 161-169
  • [6] Singer G.(2004)Clinicopathological analysis of early-stage sporadic ovarian carcinoma Am J Surg Pathol 28 147-159
  • [7] Stohr R.(2000)Promoter hypermethylation is a cause of BRCA1 inactivation in sporadic breast and ovarian tumors J Natl Cancer Inst 92 564-569
  • [8] Cope L.(2007)Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours J Pathol 211 286-295
  • [9] Medeiros F.(2005)WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma Histopathology 46 468-1329
  • [10] Muto M.G.(2003)A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 1320-921